Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 5 percent decrease over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $233.000 thousand which beat the analyst consensus estimate of $22.308 thousand by 944.48 percent. This is a 210.67 percent increase over sales of $75.000 thousand the same period last year.